StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Cancidas (caspofungin, legacy) by Quarter

Cancidas (caspofungin, legacy) — Worldwide reported growth YoY (%) (%)

QuarterlyAnnual

Merck Cancidas (caspofungin, legacy): -24.0% in Q3 2022, down 37.0 pts from a year earlier. No newer figure appears in the documents we track.

Latest, Q3 2022
-24.0%
Period ended Sep 30, 2022
Change on a year earlier
-37.0 pts
13.0% in Q3 2021
History
20 quarters
Since Q4 2017
Sources
20
Documents cited below

Where the Q3 2022 figure comes from

“|| Cancidas | 43 | 56 | -24 | 1 | 1 | 81 | 42 | 56 | -25”

Source: Form 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗

Reported in Form 8-K Table 3 / 3a / 3b Product Sales.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCancidas (caspofungin, legacy) — Worldwide reported growth YoY (%) (%)Year on yearSource
Q3 2022Sep 30, 2022-24.0%-37.0 ptsForm 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q2 2022Jun 30, 2022-23.0%-47.0 ptsForm 8-K (tm2221828d1_ex99-1.htm, filed 2022-07-28) ↗
Q1 2022Mar 31, 2022-8.0%-12.0 ptsForm 8-K (tm2213615d1_ex99-1.htm, filed 2022-04-28) ↗
Q4 2021Dec 31, 2021-31.0%-44.0 ptsForm 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
Q3 2021Sep 30, 202113.0%+33.0 ptsForm 8-K (tm2131077d1_ex99-1.htm, filed 2021-10-28) ↗
Q2 2021Jun 30, 202124.0%+60.0 ptsForm 8-K (tm2123400d1_ex99-1.htm, filed 2021-07-29) ↗
Q1 2021Mar 31, 20214.0%+14.0 ptsForm 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q4 2020Dec 31, 202013.0%+30.0 ptsForm 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
Q3 2020Sep 30, 2020-20.0%+1.0 ptsForm 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗
Q2 2020Jun 30, 2020-36.0%-14.0 ptsForm 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗
Q1 2020Mar 31, 2020-10.0%+23.0 ptsForm 8-K (tm2016917d1_ex99-1.htm, filed 2020-04-28) ↗
Q4 2019Dec 31, 2019-17.0%+10.0 ptsForm 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q3 2019Sep 30, 2019-21.0%-5.0 ptsForm 8-K (tm1921023d1_ex99-1.htm, filed 2019-10-29) ↗
Q2 2019Jun 30, 2019-22.0%+1.0 ptsForm 8-K (a19-15283_1ex99d1.htm, filed 2019-07-30) ↗
Q1 2019Mar 31, 2019-33.0%-8.0 ptsForm 8-K (a19-8996_1ex99d1.htm, filed 2019-04-30) ↗
Q4 2018Dec 31, 2018-27.0%+10.0 ptsForm 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗

Cite this data

StockData. (2026). Merck Cancidas (caspofungin, legacy) (%), quarterly Q4 2017–Q3 2022 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-cancidas-ww-nom-yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.